Cartalax 20mg
Research-grade Cartalax 20mg. 99% purity, third-party tested with published COA.
Ships from USA
1–3 day delivery
Free Shipping
On orders $150+
Peptide Handling & Storage Guide
Storage temperature, shelf life & reconstitution (PDF)
99%+ Purity
COA included
Same-Day Shipping
Orders before 2PM EST
Secure Checkout
SSL encrypted
Shipment Protection
Lost or damaged — reshipped free
Compound Information
- Type
- Synthetic tripeptide bioregulator
- Molecular Formula
- C12H19N3O8
- Molecular Weight
- 333.29 g/mol
- Purity
- 99%
- Sequence
- Ala-Glu-Asp (AED)
- Also known as
- T-31 peptide
Reference chemistry (free base) from public chemical databases and peer-reviewed literature. For laboratory research identification only.
Research Use Only. This vial is bound for the lab bench — supplied for in-vitro scientific work exclusively, never for administration to any person or animal.
About Cartalax
Cartalax is the trivial name for the tripeptide Ala-Glu-Asp (AED), one of the short "peptide bioregulators" developed by V. Kh. Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology — a family of two-to-four-residue synthetic peptides studied for tissue-associated effects on gene and protein expression in cell-culture models.
The published primary research on AED is preclinical and largely in vitro. In cultured human skin fibroblasts undergoing replicative aging, AED has been reported to increase synthesis of sirtuin-1, sirtuin-6, and type I collagen, and — alongside the related peptides KE, KED and AEDG — to raise the proliferation marker Ki-67 and reduce MMP-9. These are observations of molecular changes in laboratory models, from a single research group; they are not evidence of any clinical or health effect, and AED has not been evaluated in human clinical trials.
Frequently Asked Questions
What is Cartalax?
Cartalax is a synthetic tripeptide (Ala-Glu-Asp) in the Khavinson family of short peptide bioregulators. It is studied in laboratory and cell-culture research and is supplied for research use only, not for human or veterinary use.
What is the amino acid sequence of Cartalax?
Cartalax is the tripeptide Ala-Glu-Asp, abbreviated AED (alanine–glutamic acid–aspartic acid).
What has Cartalax been studied for in research?
Published preclinical work on the AED peptide is mainly in vitro cell-culture research on aging cells — for example, reported changes in sirtuins, type I collagen, and proliferation markers in human skin fibroblasts. These are laboratory findings only; no therapeutic effect in humans has been established.
Is Cartalax the same as Bronchogen?
No. Cartalax is the tripeptide Ala-Glu-Asp (AED); Bronchogen is a different, longer peptide, the tetrapeptide Ala-Glu-Asp-Leu (AEDL). Some listings conflate the two, but they are distinct molecules.
Is Cartalax approved for human use?
No. Cartalax is a research compound. It is not approved as a drug or supplement and is not intended for human consumption, diagnosis, or treatment.
Research & References
Independent databases and peer-reviewed literature for Cartalax. Provided for research reference only.
External resources are independent and not affiliated with or endorsed by PHIOGEN. Listed for laboratory research reference only.
